An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis
1 other identifier
interventional
22
1 country
1
Brief Summary
The purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic dermatitis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2
Started Nov 2006
Typical duration for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2008
CompletedFirst Submitted
Initial submission to the registry
December 8, 2008
CompletedFirst Posted
Study publicly available on registry
December 10, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2009
CompletedResults Posted
Study results publicly available
July 11, 2017
CompletedJuly 11, 2017
June 1, 2017
2 years
December 8, 2008
May 17, 2017
June 9, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Incidence of Skin Irritation
1 and 2 year time points
Incidence of Skin Infection
1 and 2 year timepoints
Compliance With Protocol
over two years
Secondary Outcomes (1)
Development of Eczema
1 and 2 year time points
Study Arms (1)
Emollient
EXPERIMENTALSkin barrier protection from birth
Interventions
Eligibility Criteria
You may qualify if:
- at least one parent diagnosed with Atopic Dermatitis
- one parent or sibling with hayfever or asthma
You may not qualify if:
- newborns with dermatitis at birth
- newborns born greater than four weeks prematurely
- newborns with medical problems necessitating prolonged hospitalization
- newborns diagnosed with any immune deficiency syndrome
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Oregon Health and Science Universitylead
- Galderma R&Dcollaborator
Study Sites (1)
Oregon Health & Science University, Department of Dermatology
Portland, Oregon, 97239, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Eric Simpson, MD, MCR
- Organization
- Oregon Health & Science University
Study Officials
- PRINCIPAL INVESTIGATOR
Eric Simpson, MD
Oregon Health and Science University
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor, Dermatology
Study Record Dates
First Submitted
December 8, 2008
First Posted
December 10, 2008
Study Start
November 1, 2006
Primary Completion
November 1, 2008
Study Completion
November 1, 2009
Last Updated
July 11, 2017
Results First Posted
July 11, 2017
Record last verified: 2017-06